Because there are differing opinions regarding treatment of patients in the chronic phase of
chronic myeloid leukemia (CML), the American Society of Hematology convened an expert …

Abstract Treatment for chronic myeloid leukemia (CML) has evolved from chemotherapy
(busulfan, hydroxyurea) to interferon-α (IFNα), and finally to tyrosine kinase inhibitors such …

Interferon-alpha (IFNα) was once the standard of frontline treatment for chronic myeloid
leukemia (CML). Its pleiotropic mechanism of action in CML includes immune activation and …

Type I interferons (IFNs) exhibit antiproliferative activity and apoptotic effects, and regulate
an immune response by activating multiple cells types, including dendritic cells, cytotoxic T …

Biological agents have long been used in the treatment of cancer, and interferon-alpha was
the first human cytokine to be widely studied in this setting. Chronic myeloid leukemia (CML) …

The management of chronic myelogenous leukaemia (CML) has undergone a major change
over the past 5 years. All newly diagnosedpatients of CMLarecandidatesforimatinibmesylate …

PURPOSE: To provide a status report on the use of interferon (IFN)-a in patients with chronic
myelogenous leukemia (CML). DATA SOURCES: Data on IFN-a therapy for CML collected …

A prospective randomized international study of 143 patients showed no apparent early
survival advantage conferred by combining cytarabine, rather than hydroxyurea, with INF as …

The prognostic value of different factors upon diagnosis of CML was analysed in 45
Philadelphia (Ph1)-positive patients. The median survival was 48 months. Univariate …

INTRODUCTION Philadelphia positive chronic myelogenous leukemia (Ph1+ CML) is a
myeloproliferative disorder of clonal origin, due to neoplastic transformation of a pluripotent …